4-Propoxyphenylboronic Acid | CAS:186497-67-6

We serve 4-Propoxyphenylboronic Acid CAS:186497-67-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-Propoxyphenylboronic Acid

Product Name: 4-Propoxyphenylboronic Acid
Other Name:
4-Propoxyphenylboronic Acid
(4-propoxyphenyl)boronic acid
4-propoxyphenylboric acid;
4-propoxybenzeneboronic acid
4-n-propoxyboronic acid
p-propoxyphenylboronic acid
4-n-Propoxybenzeneboronic acid
4-n-Propoxyphenylboronic acid
CAS No: 186497-67-6
MF: C9H13BO3
MW: 180.00900
Density: 1.1 g/cm3
Boiling point: 329.6ºC at 760 mmHg
Melting point: 123-126 °C(lit.)
Flash point: 153.1ºC
Refractive index: 1.514
UN Number: UN1760
Transport hazard class: 8
Packing group: III
 
Specification
Appearance: White powder
Assay: ≥98.0%
Water: ≤0.50%
 
Application
Be used as pharmaceutical intermediate.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.



Contact us for information like 4-Propoxyphenylboronic Acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-n-Propoxyphenylboronic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Propoxyphenylboronic Acid Use and application,4-Propoxyphenylboronic Acid technical grade,usp/ep/jp grade.


Related News: Taiwan previously participated as an observer at the World Health Assembly, the W.H.O.’s governing body.4-Methylbenzyl Bromide manufacturer Taiwan previously participated as an observer at the World Health Assembly, the W.H.O.’s governing body.2-Carboxyphenylboronic Acid supplier Active pharmaceutical ingredients directly impact disease.2-chloro-1-fluoro-4-isothiocyanatobenzene vendor Active pharmaceutical ingredients directly impact disease.The increase in environmental protection pressure has also increased the environmental protection expenditure of pharmaceutical manufacturing companies, which forced some small production capacity to withdraw from the market, increased industry concentration, and brought certain opportunities for API manufacturers.